CDKN1C‐mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib

Mantle cell lymphoma (MCL) is a rare subtype of non‐Hodgkin's lymphoma, which is characterized by overexpression of cyclin D1. Although novel drugs, such as ibrutinib, show promising clinical outcomes, relapsed MCL often acquires drug resistance. Therefore, alternative approaches for refractory...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Sci
Hlavní autoři: Kagiyama, Yuki, Fujita, Shuhei, Shima, Yutaka, Yamagata, Kazutsune, Katsumoto, Takuo, Nakagawa, Makoto, Honma, Daisuke, Adachi, Nobuaki, Araki, Kazushi, Kato, Ayako, Inaki, Koichiro, Ono, Yoshimasa, Fukuhara, Suguru, Kobayashi, Yukio, Tobinai, Kensei, Kitabayashi, Issay
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2021
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8177787/
https://ncbi.nlm.nih.gov/pubmed/33792119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.14905
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky